Biopharmaceutical
Timberlyne Therapeutics is a biopharmaceutical company developing novel therapies for autoimmune disorders, focusing on advancing a monoclonal antibody targeting CD38.
Biotechnology
Candid Therapeutics, Inc. is a biotechnology company developing transformative therapies for autoimmune diseases.
Cybersecurity
Zero Networks is a cybersecurity firm that offers a fully automated SaaS platform employing zero trust principles to restrict user and machine access to only necessary assets and facilitate secure remote connections.
Therapeutic Oncology
RefleXion Medical develops and commercializes SCINTIX therapy, a novel treatment for all stages of indicated solid tumor cancers, including metastatic disease, delivered via the RefleXion X1 platform.
Biopharmaceutical
MBrace Therapeutics is a biopharmaceutical company developing a lead antibody-drug conjugate (ADC) candidate, MBRC-101, targeting the EphA5 receptor tyrosine kinase present in various cancers, with the recent completion of an $85 million Series B financing round.